Design Therapeutics Inc
DSGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$948.72M
Close$
$0.27
98% downside
Current Fair Value
98% downsideOvervalued by 98% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $948.72 Million |
|---|---|
| Enterprise Value | $938.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 1.59 |
| Outstanding Shares | 61,434,457 |
Return
| Return on Equity | -31.97% |
|---|---|
| Return on Assets | -30.25% |
| Return on Invested Capital | -38.01% |
Valuation & Multiples
| P/E Ratio | -12.66 |
|---|---|
| PEG | 2838.51 |
| Price to Sales | - |
| Price to Book Ratio | 4.56 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -11.21 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 66.26% |
|---|---|
| Total Invested | $39,130▼ 99.99% |
| Investors Holding | 4▼ 120.00% |
ESG Score
No data
About Design Therapeutics Inc
15 employeesDesign Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...